Company news

PTC Therapeutics, Inc. news in 2023

PTC Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

December 4, 2023

PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results

October 25, 2023

PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion

October 18, 2023

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results

October 15, 2023

PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce

September 27, 2023

CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization

September 14, 2023

PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community

September 6, 2023

PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium

August 27, 2023

PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results

August 2, 2023

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results

July 19, 2023

PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize

July 18, 2023

PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

July 16, 2023

PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin

July 10, 2023

PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

June 28, 2023

PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients

June 20, 2023

PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial

May 22, 2023

PTC Therapeutics Announces Strategic Pipeline Prioritization

May 22, 2023

PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

May 16, 2023

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 27, 2023

PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results

April 26, 2023

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results

April 12, 2023

Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics

March 23, 2023

PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

February 20, 2023

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

February 6, 2023

PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation

February 2, 2023

NICE Recommends Reimbursement for Translarna™

January 18, 2023

PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

January 16, 2023

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference

January 8, 2023

PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Calls in 2023

Decks in 2023